Clinical Trials
35
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (33 trials with phase data)• Click on a phase to view related trials
Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
- Conditions
- Ovarian CancerEndometrial CancerOvarian Germ Cell TumorGerm Cell TumorTesticular Germ Cell Tumor
- Interventions
- First Posted Date
- 2024-02-26
- Last Posted Date
- 2025-04-13
- Lead Sponsor
- Xencor, Inc.
- Target Recruit Count
- 212
- Registration Number
- NCT06276491
- Locations
- 🇺🇸
Winship Cancer Institute, Emory University, Atlanta, Georgia, United States
🇺🇸Icahn School of Medicine at Mount Sinai, New York, New York, United States
🇺🇸Karmanos Cancer Institute, Detroit, Michigan, United States
Study of Vudalimab or Pembrolizumab in Combination With Chemotherapy as First-line Treatment in Patients With Advanced NSCLC
- Conditions
- Nonsquamous Non-small Cell Lung Cancer
- First Posted Date
- 2023-12-15
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Xencor, Inc.
- Target Recruit Count
- 168
- Registration Number
- NCT06173505
- Locations
- 🇺🇸
Memorial Cancer Institute at Memorial Hospital West, Pembroke Pines, Florida, United States
🇺🇸Midwestern Regional Medical Center, Zion, Illinois, United States
🇬🇷Athens Medical Center, Athens, Greece
Multiple Ascending-Dose Study of XmAb®27564 in Patients With Psoriasis or Atopic Dermatitis
- Conditions
- PsoriasisAtopic Dermatitis
- First Posted Date
- 2023-08-22
- Last Posted Date
- 2024-05-16
- Lead Sponsor
- Xencor, Inc.
- Target Recruit Count
- 128
- Registration Number
- NCT06005792
- Locations
- 🇺🇸
Unison Clinical Trials, Sherman Oaks, California, United States
🇺🇸Clinical Trials Research Institute, Thousand Oaks, California, United States
🇺🇸Driven Research, Coral Gables, Florida, United States
A Study of XmAb®662 as Monotherapy or in Combination With Pembrolizumab in Advanced Solid Tumors
- Conditions
- Solid Tumors
- First Posted Date
- 2023-08-18
- Last Posted Date
- 2024-08-23
- Lead Sponsor
- Xencor, Inc.
- Target Recruit Count
- 7
- Registration Number
- NCT05996445
- Locations
- 🇺🇸
Sarah Cannon Research Institute at HealthONE, Denver, Colorado, United States
🇺🇸Icahn School of Medicine at Mount Sinai, New York, New York, United States
🇺🇸University Of Virginia Comprehensive Cancer Center, Charlottesville, Virginia, United States
Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizumab in Advanced Solid Tumors
- Conditions
- Melanoma Excluding Uveal MelanomaOvarian Cancer, EpithelialHead and Neck Squamous Cell CarcinomaNon-small Cell Lung Cancer, Squamous or Non-squamousRenal Cell Carcinoma, Clear CellTNBC - Triple-Negative Breast CancerColorectal CancerCastration-resistant Prostate CancerUrothelial Carcinoma
- Interventions
- Biological: XmAb®808
- First Posted Date
- 2022-10-18
- Last Posted Date
- 2025-03-28
- Lead Sponsor
- Xencor, Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT05585034
- Locations
- 🇺🇸
UCLA Hematology/Oncology, Los Angeles, California, United States
🇺🇸Sarah Cannon Research Institute at HealthONE, Denver, Colorado, United States
🇺🇸Florida Cancer Specialists, Sarasota, Florida, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- Next
News
Federal Circuit Ruling Opens New Patent Challenge Avenue for Life Sciences Companies
The U.S. Court of Appeals for the Federal Circuit's decision in Xencor Inc. case provides drugmakers with a new strategy to challenge patents by focusing on inadequate written descriptions in Jepson claims.